Takeda Q1 FY2026 Core Revenue Dips 0.5% CER; Pipeline and Launch Updates Signal H2 Recovery
Takeda Pharmaceutical reported Q1 FY2026 core revenue declining 0.5% on a constant exchange rate basis.
Read the full story on market.news
🇯🇵 Japan Stocks Earnings japan pharma asia earnings-miss
What is your take? Drop your thoughts below. 